Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05063565
Title TheraSphere With and Without Durvalumab and Tremelimumab for HCC (ROWAN)
Acronym ROWAN
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boston Scientific Corporation
Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.